ESMO 2021: SunRISe-1: TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High Risk NMIBC Unresponsive to Intravesical BCG Who Are Ineligible for or Elected Not To Undergo Radical Cystectomy

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Michiel Van der Heijden presented on the design of the SunRISe-1 trial (NCT04640623).